Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC

Opinion
Video

The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.

Related Videos
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Sumanta Kumar Pal, MD, FASCO,
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Stephen V. Liu, MD
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
Related Content
Ken Takeshita, MD

Dato-DXd Does Not Elicit Significant OS Improvement in Previously Treated, Advanced NSCLC

May 28th 2024
Article
Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

May 23rd 2024
Podcast
FDA

FDA Grants Breakthrough Therapy Designation to NVL-655 for Pretreated ALK+ NSCLC

May 17th 2024
Article
Matthew Lunning, DO, FACP, associate professor, the Division of Oncology & Hematology, associate vice chair, research, the Department of Internal Medicine, assistant vice chancellor, clinical research, the University of Nebraska Medical Center

Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies

March 18th 2024
Podcast
FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC

FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC

May 16th 2024
Article
Lung Cancer | Image Credit: © Axel Kock - stock.adobe.com

When Lung Cancer Took One Lung and COVID Took the Other, a Chicago Police Captain Was Left With Only One Option for Survival

May 16th 2024
Article